Strength Training Fights Inflammaging in Bone Marrow Transplant Survivors
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
20 articles
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
A Columbia University trial tested a digital care service to improve immunotherapy outcomes and reduce healthcare burden for minority lung cancer patients.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
A Swiss feasibility trial tests digital mindfulness-based cancer recovery, tracking psychosocial outcomes, medication use, and biological markers.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.